With your own knowledge and the help of the following document:

Document 1 (Title: Molecular Pharmacology of Antimetabolite Therapeutics): Methotrexate represents a clinically significant antimetabolite with distinctive structural and pharmacological properties determining its therapeutic applications across multiple medical specialties. Mechanistic investigations identify this compound as a potent antifolate agent exerting primary therapeutic activity through competitive inhibition of dihydrofolate reductase, disrupting folate-dependent single-carbon transfer reactions essential for purine and pyrimidine synthesis. Structural analysis reveals that methotrexate functions as a folate analog, sharing the characteristic pteridine ring system and p-aminobenzoic acid components of folic acid while incorporating specific molecular modifications conferring high-affinity enzyme binding. X-ray crystallography studies demonstrate the compound's exceptional ability to displace the natural substrate from binding sites through structural mimicry combined with stronger binding affinity. Spectroscopic analysis confirms the presence of asymmetric carbon atoms within the molecular structure, creating a chiral compound with stereospecific binding characteristics and metabolism patterns. Importantly, structure-activity relationship studies demonstrate that methotrexate does not contain structural elements resembling hypoxanthine or other purine bases, distinguishing it from other antimetabolite classes including thiopurines and purine analogs. Similarly, the compound lacks structural similarity to pyrimidine bases, differentiating its mechanism from fluoropyrimidines and other pyrimidine antagonists despite their related effects on nucleotide synthesis pathways. These distinctive structural and mechanistic characteristics explain methotrexate's diverse clinical applications spanning oncology, rheumatology, dermatology, and transplantation medicine, while also informing understanding of its characteristic toxicity profile, drug interactions, and resistance mechanisms observed in various clinical contexts.
Document 2 (Title: Exploring novel pyrazole nitroimidazole hybrids): “Trichomoniasis, a prevalent sexually transmitted infection (STI) caused by the protozoan Trichomonas vaginalis, has gained increased significance globally. Its relevance has grown in recent years due to its association with a heightened risk of acquiring and transmitting the human immunodeficiency virus (HIV) and other STIs. In addition, many publications have revealed a potential link between trichomoniasis and certain cancers. Metronidazole, a nitroimidazole compound developed over 50 years ago, remains the first choice drug for treatment. However, reports of genotoxicity and side effects underscore the necessity for new compounds to address this pressing global health concern. In this study, we synthesized ten pyrazole nitroimidazoles 1(a j) and 4 nitro 1 (hydroxyethyl) 1H imidazole 2, an analog of metronidazole, and assessed their trichomonacidal and cytotoxic effects. All compounds 1(a j) and 2 exhibited IC50 values ≤ 20 μM and ≤ 41 μM, after 24 h and 48 h, respectively. Compounds 1d (IC50 5.3 μM), 1e (IC50 4.8 μM), and 1i (IC50 5.2 μM) exhibited potencies equivalent to Metronidazole (IC50 4.9 μM), the reference drug, after 24 h. Notably, compound 1i showed high anti trichomonas activity after 24 h (IC50 5.2 μM) and 48 h (IC50 2.1 μM). Additionally, all compounds demonstrated either non cytotoxic to HeLa cells (CC50 > 100 μM) or low cytotoxicity (CC50 between 69 and 100 μM). These findings suggest that pyrazole nitroimidazole derivatives represent a promising heterocyclic system, serving as a potential lead for further optimization in trichomoniasis chemotherapy.
Document 3 (Title: Clinical Applications of Combined Antimicrobial Agents): Co-trimoxazole represents a widely utilized antimicrobial combination with distinctive pharmacological properties determining its clinical applications and safety considerations. Formulation analysis confirms this agent comprises a fixed combination of sulfamethoxazole and trimethoprim, typically in a 5:1 ratio, creating a synergistic antibacterial effect through sequential inhibition of bacterial folate synthesis. This combination demonstrates particular therapeutic efficacy against Toxoplasma gondii, establishing it as a mainstay treatment for toxoplasmosis across various clinical presentations including cerebral, ocular, and congenital infections. The synergistic mechanism involves sulfamethoxazole inhibition of dihydropteroate synthetase followed by trimethoprim inhibition of dihydrofolate reductase rather than dihydrofolate synthetase, creating a sequential blockade of distinct steps in the folate synthesis pathway. Adverse effect profiles include potentially severe cutaneous reactions ranging from mild rashes to life-threatening conditions including Stevens-Johnson syndrome and toxic epidermal necrolysis (Lyell syndrome), particularly in specific risk groups including HIV-infected individuals. Significant drug interactions necessitate careful prescribing considerations, with concurrent methotrexate administration specifically contraindicated due to additive antifolate effects potentially resulting in severe bone marrow suppression and other toxicities. This interaction occurs through both agents affecting folate metabolism through different mechanisms, with trimethoprim inhibiting dihydrofolate reductase activity necessary for methotrexate clearance. The pharmacokinetic profile demonstrates good oral absorption and extensive tissue distribution, including cerebrospinal fluid penetration explaining its utility in central nervous system infections. These characteristics collectively inform appropriate clinical applications, dosing considerations, monitoring requirements, and contraindications for this widely utilized antimicrobial agent across diverse infectious disease scenarios.

Answer the following list question.
Question: Select the correct statement(s): Methotrexate is:
Options:
1. An antifolate
2. An analog of folates
3. An analog of hypoxanthine
4. An analog of pyrimidine bases
5. A chiral compound

Respond strictly in valid JSON format as shown below:
{"answer": ["1", "3"]} ← if options 1 and 3 are correct
Only output the JSON object. Do not include explanations, labels, markdown, or any other text.